Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Medtronic
Moodys
McKinsey
Harvard Business School

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Tegafur

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Tegafur?

Tegafur is an investigational drug.

There have been 122 clinical trials for Tegafur. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.

The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Pharmaceutical Co., Ltd., and National Taiwan University Hospital.

There are two US patents protecting this investigational drug and twenty-nine international patents.

Recent Clinical Trials for Tegafur
TitleSponsorPhase
Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction AdenocarcinomaRenJi HospitalPhase 2
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic CancerFudan UniversityPhase 2
A Study of Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric CancerCSPC Ouyi Pharmaceutical Co., Ltd.Phase 3

See all Tegafur clinical trials

Clinical Trial Summary for Tegafur

Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur

See all Tegafur clinical trials

US Patents for Tegafur

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegafur   Start Trial Heterocyclic compounds useful in the treatment of disease Epigen Biosciences, Inc. (San Diego, CA)   Start Trial
Tegafur   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Tegafur   Start Trial Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same Protalix Ltd. (Carmiel, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Johnson and Johnson
Dow
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.